1-20 of 27
Keywords: Survival
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2024) 47 (9): 401–409.
Published Online: 22 July 2024
..., metastasis site, serum LDH level, response to chemotherapy, and disease recurrence. Outcomes in LD-SCLC patients were found to be similar between sexes; median overall survivals in women compared to men was 18 versus 15 months, respectively ( p = 0.8). On the other hand, female patients with ED-SCLC had...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2022) 45 (12): 728–735.
Published Online: 15 June 2022
... included age at diagnosis, stage of disease, cause of death, interval time between BC and USC diagnosis, and overall survival. Results: The SEER database included 10,021 patients with USC during the years 1975–2015. 698 (6.96%) of these patients had been previously diagnosed with BC. The incidence of USC...
Journal Articles
Oncol Res Treat (2022) 45 (1-2): 12–17.
Published Online: 18 November 2021
... the regimen as salvage therapy after disease progression from previous therapy. Sixty-five point six percentage of patients showed visceral metastases. The CBR was 31.2%, and the median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI] 3.6–4.7). No grade 3–4 adverse events were...
Journal Articles
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2021) 44 (7-8): 408–413.
Published Online: 21 July 2021
... of CRT, 6 of which were definitive. Surgery was either palliative ( n = 6) or radical ( n = 15). Results: After RT, the median overall survival (OS) was 10.4 months (m), median progression-free survival was 5.6 m, and median duration of local control (DOLC) was 8.9 m. There was a significant difference...
Journal Articles
Oncol Res Treat (2021) 44 (5): 252–260.
Published Online: 28 April 2021
...-expressive group therapy (SEGT) can potentially benefit these patients. Objective: This systematic review and meta-analysis evaluated the effectiveness of SEGT for women with breast cancer, by focusing on survival, QoL, anxiety, and depression as outcomes. Methods: The Preferred Reporting Items...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2021) 44 (1-2): 28–35.
Published Online: 11 December 2020
... in a population-based registry. Methods: A retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) database was conducted to compare the outcomes of thymoma patients with or without PORT. The primary outcomes were overall survival (OS) and cancer-specific survival (CSS). Conditional...
Journal Articles
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2020) 43 (7-8): 362–371.
Published Online: 08 June 2020
... of modern immunohistochemistry (IHC)-based BC subtypes on long-term mortality. Method: We used a cohort of 200 women diagnosed with stage I–III BC in the period 1985–1990. Surgical samples underwent centralized pathology review. Multivariate models assessed associations of subtype with overall survival (OS...
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2019) 42 (10): 506–514.
Published Online: 23 July 2019
...Abdullah Sakin; Suleyman Sahin; Nurgul Yasar; Cumhur Demir; Serdar Arici; Caglayan Geredeli; Sener Cihan Purpose: To determine whether hemogram parameters have prognostic effects on survival in patients with extensive-stage small cell lung cancer (ED-SCLC). Methods: This retrospective analysis...
Journal Articles
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (4): 206–213.
Published Online: 23 March 2018
...). The objective response rate to first-line palliative systemic therapy was 20% and the median progression-free survival was 4.9 months (range 0.1-17.1). The median survival from diagnosis of metastasis was 20.5 months (range 0.4-126.9). On multivariate analysis, metachronous disease, no progressive disease...
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2017) 40 (12): 784–788.
Published Online: 29 November 2017
.... The majority were male (56%) and had distant metastases (74%). Chemotherapy was the major modality of treatment (86%) with a median overall survival (OS) of 33.3 weeks (range 1.7-245.4 weeks). Chemotherapy significantly (p < 0.001) improved OS in comparison to best supportive care only (37.6 vs. 13.9 weeks...
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2017) 40 (6): 370–374.
Published Online: 10 May 2017
.... In addition, high expression of NORAD was correlated with larger tumor size (p = 0.021) and T stage (p = 0.045). Kaplan-Meier analysis indicated that patients with high NORAD expression had poor overall and disease-free survival (p < 0.001). Moreover, multivariate analysis showed that increased expression...